Innate reports additional Phase I data for IPH4102 in cutaneous T cell lymphoma (CTCL)

In October, Innate Pharma S.A. (Euronext:IPH) reported additional data from the dose escalation portion of the Phase I IPH4102-101 trial. Among 20 patients with relapsed or refractory Sezary syndrome

Read the full 297 word article

User Sign In